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Nonsustained Ventricular Tachycardia
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Nonsustained ventricular tachycardia (NSVT) has been recorded in a wide range of conditions, from apparently
healthy individuals to patients with significant heart disease. In the absence of heart disease, the prognostic sig-
nificance of NSVT is debatable. When detected during exercise, and especially at recovery, NSVT indicates in-
creased cardiovascular mortality within the next decades. In trained athletes, NSVT is considered benign when
suppressed by exercise. In patients with non–ST-segment elevation acute coronary syndrome, NSVT occurring
beyond 48 h after admission indicates an increased risk of cardiac and sudden death, especially when associ-
ated with myocardial ischemia. In acute myocardial infarction, in-hospital NSVT has an adverse prognostic signif-
icance when detected beyond the first 13 to 24 h. In patients with prior myocardial infarction treated with reper-
fusion and beta-blockers, NSVT is not an independent predictor of long-term mortality when other covariates
such as left ventricular ejection fraction are taken into account. In patients with hypertrophic cardiomyopathy,
and most probably genetic channelopathies, NSVT carries prognostic significance, whereas its independent prog-
nostic ability in ischemic heart failure and dilated cardiomyopathy has not been established. The management
of patients with NSVT is aimed at treating the underlying heart disease. (J Am Coll Cardiol 2012;60:
1993–2004) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.063Nonsustained ventricular tachycardia (NSVT) is defined as
3 (sometimes 5) or more consecutive beats arising below the
atrioventricular node with an RR interval of 600 ms
(100 beats/min) and lasting 30 s (1). This definition,
owever, is not universal. NSVT has also been defined as
uns of 16 beats with a rate 125 beats/min (2) or 120
beats/min (3), using a time cutoff of 15 s (4), or even
without strictly defined diagnostic criteria (5). Thus, reliable
epidemiological data on NSVT are difficult to obtain,
particularly because reproducibility of NSVT recordings on
Holter monitoring is documented in only half of the
patients with this arrhythmia (6). Although NSVT may
cause symptoms of palpitations, usually it is asymptomatic
because of its brevity and the nature of the short-lived
episodes of arrhythmia may not allow a clear distinction
between monomorphic and polymorphic ventricular
rhythms. When NSVT is documented in the context of a
history of established monomorphic VT, it is usually mono-
morphic and may demonstrate the same morphology and
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2011, accepted December 20, 2011.share the same mechanism with the clinical sustained
arrhythmia, especially in cases of idiopathic VT.
In several clinical settings, NSVT is a marker of increased
risk for subsequent sustained tachyarrhythmias and sudden
cardiac death (SCD), whereas it may have no prognostic
significance in others. The important tasks of the physician
are to detect those apparently healthy individuals in whom
NSVT represents a sign of occult disease, and to risk-
stratify patients with known disease who present with this
arrhythmia to provide therapy that mitigates associated
risks. This may not always be easy in clinical practice.
Whether NSVT provokes sustained, life-threatening ar-
rhythmias or is simply a surrogate marker of a more severe
underlying pathology is still unknown in most clinical
settings.
NSVT in Apparently Normal Heart
In asymptomatic, apparently healthy persons, NSVT epi-
sodes may be recorded at rest (7–9). Although Framingham
data have suggested an association with increased mortality
(7), especially in persons with left ventricular hypertrophy
(8), the prognostic significance of spontaneous NSVT
recorded in apparently healthy individuals has not been
established (9). Recent data have demonstrated that runs of
2 consecutive ventricular depolarizations during exercise
or at recovery may occur in up to 3% of healthy men and
predict an increase in cardiovascular mortality within the
next 23 years by a factor of more than 2.5 (10). Frequent
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death than ventricular ectopy oc-
curring only during exercise (11).
NSVT may also be recorded in
professional athletes without struc-
tural heart disease but is considered
benign and without long-term im-
plications when suppressed by exer-
cise (12–14). Arrhythmia episodes
decrease during periods of decondi-
tioning, and resumption of training
is safe (15,16). The mechanism of
NSVT in this setting is unknown. A
shift of autonomic modulation from
parasympathetic to sympathetic pre-
dominance induced by intensive
endurance training and sinus brady-
cardia–induced ventricular ectopy
have been postulated (15). NSVT in
athletes is considered part of the
“athlete’s heart syndrome” (12,15)
and has no adverse prognostic sig-
nificance, provided conditions such
as hypertrophic cardiomyopathy
(HCM), early repolarization syn-
drome, and other genetic chan-
nelopathies are excluded. The early
repolarization pattern, manifested
as QRS slurring or notching, has
long been considered to be a be-
nign electrocardiogram (ECG)
manifestation that is seen more
commonly in young healthy men
and athletes (17), but there has
been evidence suggesting that it
may be associated with a risk for
ventricular fibrillation (VF), depending on the magnitude of
the J wave and degree of ST elevation (18–22). A horizon-
tal/descending type (defined as 0.1 mV elevation of the
ST segment within 100 ms after the J point) may help to
identify those individuals who are clearly at risk (23).
Age, general condition, previous medical history, history
of sudden death and syncopal episodes in family members,
and conditions such as electrolyte disturbances, metabolic
imbalance, and proarrhythmic effect of drugs should be
considered. Ischemic heart disease (IHD) should be ex-
cluded in patients age 40 years with episodes of NSVT.
efore age 40 years, patients should be evaluated primarily
o rule out nonischemic causes of arrhythmia, including
atent hypertension and valve disease, cardiomyopathies,
nd inherited channelopathies such as long QT syndrome
LQTS), catecholaminergic polymorphic VT, Brugada syn-
rome, and other early repolarization syndromes that usu-
lly present with polymorphic episodes (Fig. 1, Table 1).













IHD  ischemic heart
disease
LBBB  left bundle branch
block
LQTS  long QT syndrome
LVEF  left ventricular
ejection fraction
LVOT  left ventricular
outflow tract
MI  myocardial infarction






RBBB  right bundle
branch block
RVOT  right ventricular
outflow tract
SCD  sudden cardiac
death
VF  ventricular fibrillationphic episodes, nonsustained or sustained, suggest idiopathicVT or arrhythmogenic right ventricular cardiomyopathy
(ARVC). Electrophysiology testing is usually performed as
part of a planned ablation procedure in medically refractory
patients and may be required to differentiate NSVT from
short runs of atrial fibrillation in the context of an accessory
pathway or other forms of aberration when this cannot be
done from surface tracings (Table 1). When no pathology is
identified, the tachycardia does not need specific therapy
other than for symptomatic relief, but follow-up of the
patient is advisable because inherited channelopathies may
remain latent for several years (24).
Idiopathic VT. Monomorphic episodes of NSVT in ap-
parently healthy individuals are often due to idiopathic
ventricular outflow arrhythmias usually present in the form
of repetitive uniform premature ventricular contractions
(PVCs), repetitive monomorphic NSVT originally described
by Gallavardin (that usually disappears as the heart rate
increases with exercise), and paroxysmal sustained monomor-
phic VT (that is usually exercise provoked) (25,26). These
tachycardias are adrenergically mediated and sensitive to aden-
osine or verapamil, which lower intracellular calcium level.
Thus, triggered activity secondary to cAMP-mediated delayed
after-depolarizations is the most probable mechanism (26).
Tachycardias mainly (70% to 80%) arise in the right
ventricular outflow tract (RVOT) and rarely below it, and
20% to 30% from the left ventricular outflow tract (LVOT).
The tachycardia often occurs during exercise but disappears
as the heart rate increases and returns during the recovery
period (25). Repetitive behavior has also been documented
in various clinical settings, including cardiomyopathy and
previous myocardial infarction (MI) (27), as well as idio-
pathic VT originating in the aortic valve cusps (28). When
Figure 1 Clinical Approach to the Patient With NSVT
CAD  coronary artery disease; CPVT  catecholaminergic polymorphic ventric-
ular tachycardia; LQTS  long QT syndrome; NSVT  nonsustained ventricular
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November 13, 2012:1993–2004 Nonsustained Ventricular Tachycardiaa 12-lead ECG displaying NSVT runs is available, RVOT
tachycardias produce a left bundle branch block (LBBB)
pattern with inferior axis and R/S transition at or beyond
V4. LVOT tachycardias may produce a right bundle branch
block (RBBB) morphology with inferior axis and R/S
transition at V1 or V2. The presence of NSVT in patients
ith idiopathic ventricular outflow tract arrhythmias indi-
ates a higher propensity for inducibility of VT during
ntracardiac electrophysiology study (EPS) compared with
solated PVCs (48% vs. 4%). At exercise, the incidence of
T in this group is 10% (26). The diagnosis of RVOT
diopathic NSVT must be differentiated from that of
RVC or other forms of cardiomyopathy (Fig. 2) (29). This
s not always straightforward because patients with RVOT
T may have subtle structural and functional abnormalities
f the RVOT as detected by magnetic resonance imaging-
MRI) (30) or myocardial biopsy (31). QRS duration in lead
of 120 ms, earliest-onset QRS in lead V1, QRS
Specific Management of NSVTTable 1 Specific Management of NSVT
Clinical Setting Investiga
Idiopathic NSVT Differentiate from ARVC
Arrhythmogenic ventricular cardiomyopathy Value of EPS not established;
intermediate arrhythmic ris
Hypertension, valve disease No need for specific managem
Non-STE ACS, NSVT 48 h after admission Meticulous ischemia testing
Acute MI, NSVT 13–24 h until
pre-discharge
Routine for acute MI
Previous MI with LVEF of 31%–40% Ischemia testing; EPS†
Previous MI with LVEF 30% or LVEF 35%
and NYHA functional class II/III
Ischemia testing; no EPS†
Asymptomatic CAD with EF 40% Ischemia testing
Syncope in CAD with EF 40% Ischemia testing; EP testing†
Nonischemic dilated cardiomyopathy Value of EP testing not establi
Hypertrophic cardiomyopathy Evaluate additional risk factors
unexplained syncope, mass
(30 mm), hypotensive or




Long QT syndrome Genotype analysis useful
Catecholaminergic polymorphic VT Value of EP testing not establi
Brugada syndrome Value of EP testing disputed
*Optimal medical therapy for NSVT in the setting of CAD is defined as administration of beta-blo
inhibitors or angiotensin receptor blockers. †If conditions remain the same after indicated revasc
that of VT induced by 1 or 2 extrastimuli. Monomorphic VT, as opposed to VF, usually does not re
recommended if indications exist 40 days after MI.
ARVC  arrhythmogenic right ventricular cardiomyopathy; CAD  coronary artery disease;
PS  electrophysiology study; ICD  implantable cardioverter-defibrillator; LVEF  left ventricula
syndrome (non–ST-segment elevation myocardial infarction or unstable angina); NSVT nonsusta
fibrillation; VT  ventricular tachycardia.notching, and a transition of V5 or later predict the presenceof ARVC (32). NSVT originating from the RVOT may
occasionally cause syncope, although the risk of death is very
low. Short cycle length during NSVT and history of
syncope are predictors of coexistence of VF or polymorphic
VT (33). In apparently normal hearts, NSVT due to bundle
branch re-entry may be seen (34). The 12-lead ECG, when
obtainable, may show either LBBB or RBBB pattern depending
on the orientation of activation of the bundle branches. Micro-
reentry within the Purkinje network may produce NSVT, or
sustained VT, with a narrow QRS and RBBB with left axis
(microreentry in the posterior fascicle), or rarely, inferior axis
(anterior fascicle) (35,36).
In symptomatic patients, treatment should be directed
toward relief of tachycardia-related symptoms with beta-
blockers or calcium-channel blockers and adenosine, if
needed in an acute setting. Class IC antiarrhythmic drugs,
preferably in combination with beta-blockers (37), because,
by definition, IHD or LV hypertrophy have been excluded,
Therapy
Beta-blockers, calcium-channel blockers; RF ablation if




Not established; perhaps amiodarone or sotalol;
ICD frequently considered
Optimal antihypertensive therapy including
beta-blockers
Revascularization and optimal medical therapy*
Revascularization and optimal medical therapy
Revascularization and optimal medical therapy;
if EP-inducible monomorphic VT or VF,‡ ICD§
Revascularization and optimal medical therapy;
ICD§
Revascularization and optimal medical therapy;
no need for specific NSVT therapy
Revascularization and optimal medical therapy;
if EP-inducible monomorphic VT or VF,‡ ICD
Optimal CCF therapy (medical and CRT if indicated);
ablation for bundle branch re-entry; ICD for syncope





Beta-blockers; ICD, especially with frequent and
prolonged (10 beats) episodes of NSVT
Predictive value of NSVT not established; consider
corrective surgery; if VT inducible, ablation and ICD
Beta-blockers; if syncope despite beta-blockers, ICD
Beta-blockers and perhaps calcium-channel blockers;
if cardiac arrest, ICD
Possibly quinidine (more data needed);
if cardiac arrest, ICD
essential unless absolutely contraindicated), aspirin, statins, and angiotensin-converting enzyme
ion. ‡Prognostic significance of inducible monomorphic VT induced by 3 extrastimuli is similar to
to revascularization. VF induced by 3 extrastimuli may represent a nonspecific response. §ICD is
congestive cardiac failure; CRT  cardiac resynchronization therapy; EF  ejection fraction;
ion fraction; MI  myocardial infarction; non-STE ACS: non–ST-segment elevation acute coronary
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Nonsustained Ventricular Tachycardia November 13, 2012:1993–2004quency catheter ablation is recommended and is successful
in more than 80% of cases with a low risk of relapse during
follow-up (38).
Genetic channelopathies. Patients with Brugada syndrome
also have an apparently normal heart, and the resting ECG
may not always display the typical Brugada type 1 pattern.
Although there are no systematic studies evaluating prognostic
significance of NSVT in Brugada syndrome, there is agree-
ment that symptomatic patients (i.e., those with syncope or
cardiac arrest) should be treated with implantable cardioverter-
defibrillators (ICDs) (39).
Usually cardiac events in LQTS, which can also be latent,
are due to prolonged NSVT episodes that might degenerate
into VF (40). However, transient, asymptomatic runs of
polymorphic NSVT are also common. The morphologically
distinctive torsade de pointes QRS may also present as a
nonsustained tachycardia that occurs in 3 common settings:
congenital LQTS, drug-associated QT prolongation, and
patients with advanced conduction system disease that has
progressed to heart block (41). Typically, there is a long
(600 to 800 ms) coupling interval of the initial beat of the
torsades, whereas the last QRS complex of the episode is
longer than the normal QRS during sinus rhythm. The
Figure 2
Runs of Pleomorphic (>1 Monomorphic Morphology)
NSVT Recorded in a 52-Year-Old Man Referred for
Catheter Ablation
Magnetic resonance imaging disclosed pathology of both the septal and lateral
areas of the right ventricle, thus suggesting cardiomyopathy rather than idio-
pathic VT. The patient was treated with catheter ablation of the predominant
ectopic morphology and cardioverter-defibrillator implantation. Abbreviations as
in Figure 1.tachycardia that usually occurs in the setting of bradycardiaor long post-ectopic pauses is often repetitive and may
trigger VF. A variety of torsades initiating with a short
coupling interval in patients without any evidence of LQTS
and that could be nonsustained has also been described (42).
Beta-blockers are the therapy of choice in patients with
LQTS (43), but their effectiveness is reduced in LQT2 and
LQT3 (44). Patients with recurrent syncope despite beta-
blocker therapy as well as asymptomatic patients with a
QTc 550 ms and additional risk factors should be con-
sidered for ICD therapy (45).
Exercise may also induce NSVT in patients with familial
catecholaminergic polymorphic VT. Arrhythmias in this
rare but very lethal condition may originate from the LVOT
and less frequently from the RVOT or RV apex. QRS
morphology suggests an outflow tract origin of the initiating
beat in more than 50% of patients, and subsequent beats
portray a polymorphic or typically bidirectional VT mor-
phology (46). NSVT induced by treadmill exercise testing
aimed at evaluating presumed LQTS suggests cat-
echolaminergic polymorphic VT rather than LQTS (47).
Beta-blocker therapy is the treatment of choice, probably
together with calcium-channel blockers (48). Defibrillator
implantation may be necessary in addition to beta-blockers
in patients with syncope or VT (49).
Systemic Hypertension and Valve Disease
In systemic hypertension (50,51) and valvular disease (52),
ventricular arrhythmias are common but less well character-
ized and usually represent polymorphic rhythms. In patients
with arterial hypertension, NSVT is correlated with the
degree of cardiac hypertrophy and subendocardial fibrosis.
Approximately 12% to 28% of patients with hypertension
and LV hypertrophy present with NSVT as opposed to 8%
of patients with hypertension alone (50,51). The exact
mechanism of ventricular arrhythmia in hypertension or
valve disease is not known. Stretch-induced abnormal au-
tomaticity or triggered activity, fibrotic tissue and loss of
connections between cell bundles that promotes re-entry,
and subendocardial ischemia have been proposed (52).
The prognostic value of NSVT in patients with lone
hypertension (without evidence for concomitant IHD) re-
mains unclear. In patients with valvular disease, the inci-
dence of NSVT is considerable (up to 25% in aortic stenosis
and in significant mitral regurgitation) and appears to be a
marker of underlying LV pathology (52). Presence of
NSVT is usually associated with LV hypertrophy or dys-
function, but no convincing evidence exists to prove that
NSVT is an independent predictor of sudden death in
patients with valve disease. Kilgfield et al. (53) estimated the
annual risk of SCD in patients with mitral valve prolapse at
1.9 of 10,000 patients, lower than the annual risk of SCD
from all causes in the adult population in the United States.
A multivariate analysis also failed to identify ventricular
arrhythmias (as opposed to New York Heart Association
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mitral prolapse (54). Most of the reported patients with
mitral valve prolapse demonstrate LBBB morphology dur-
ing tachycardia, thus raising the possibility that the mitral
valve prolapse might be an incidental finding or that the
arrhythmia is due to other mechanisms not directly related
to the mechanical stress imposed upon the ventricle by the
valvular apparatus (54,55). The occurrence of NSVT in
patients with hypertension requires evaluation of IHD.
Aggressive treatment of hypertension (including beta-
blockers) is the therapy of choice in patients with hyperten-
sion and NSVT. There is no evidence that NSVT after
valve replacement carries adverse prognostic significance.
The majority of patients with mitral valve prolapse and
NSVT do not require extensive diagnostic evaluation or
treatment (Table 1). In symptomatic patients with NSVT,
beta-blockers are considered the first-line therapy.
Coronary Artery Disease
Non–ST-segment elevation acute coronary syndromes.
In non–ST-segment elevation acute coronary syndromes,
NSVT is detected in 18% to 25% of patients 2 to 9 days
after admission (56), and even short episodes of VT lasting
4 to 7 beats are independently associated with the risk of
SCD over the subsequent year. In the MERLIN-TIMI 36
(Metabolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Elevation Acute Coronary Syndromes–Thrombolysis
in Myocardial Infarction 36) trial in 6,300 patients who had
7-day continuous ECG monitoring, there was a 2-fold
increase in the risk of SCD in patients with NSVT
occurring 48 h after admission (56). There was no
ncreased risk of SCD in patients with ventricular triplets,
nd earlier episodes within 48 h after admission did not
arry the same risk. The coexistence of NSVT with myo-
ardial ischemia, defined as1 mm ST-segment depression
lasting 1 min, indicated 10% risk of sudden death, with
ost episodes occurring within the first 3 months after the
ocumentation of NSVT and ischemia (Fig. 3) (57).
Myocardial infarction. In acute MI, NSVT during the
first 24 h is frequent (45% in patients without thrombolysis
and up to 75% in reperfused patients) (1,58). Following the
first 7 days after MI, NSVT is detected in approximately
6.8% to 13.4% of patients in the reperfusion era (59–62),
which is not much different than that reported in the
pre-thrombolysis era (63). The detected incidence of NSVT
by a cardiac monitor implanted 2 to 5 days after MI in
patients with LVEF 40% over a 2-year period was 13%
(2). Usually monomorphic NSVT is seen in the context of
re-entry at the borders of a ventricular scar due to
previous MI, whereas ischemia most of the time induces
polymorphic NSVT/VF (64). The QRS morphology
during monomorphic tachycardia may show either RBBB
or LBBB pattern or may even be nonspecific (Fig. 4).
Both RBBB and LBBB patterns can be seen in the same
patient when the infarct scar involves the interventricularseptum. The coexistence of necrotic and viable myocar-
dium, as well as increased LV mass and end-systolic
volume, predict NSVT (65).
In acute MI, NSVT during the first 13 (66) to 24 h (58)
does not carry prognostic significance. In-hospital NSVT
beyond this period indicates increased in-hospital mortality.
Following discharge, NSVT after MI predicted higher
long-term mortality in earlier studies (67,68). Evidence
from the reperfusion era suggests that NSVT no longer
appears to be an independent predictor of death in the
patient with IHD if other factors such as EF are taken into
account (4,59). NSVT has not been found to be an
independent predictor of arrhythmic or total mortality in
the studies of Hohnloser et al. (325 patients with MI) (60)
and DANAMI-2 (Danish Trial in Acute Myocardial In-
farction-2; 501 patients with fibrinolysis and 516 patients
with primary angioplasty) (61). In a study of 2,130 infarct
Figure 3 Cumulative Incidence of
Cardiovascular Death and Sudden Cardiac Death
Cumulative incidence of (A) cardiovascular death and (B) sudden cardiac
death according to presence of VT, ischemia, or both in patients with
non–ST-segment elevation acute coronary syndrome and NSVT recorded by
7-day continuous electrocardiogram monitoring. HR  hazard ratio; MI  myo-
cardial infarction; TIMI  Thrombolysis In Myocardial Infarction; other abbrevia-
tions as in Figure 1. Reproduced with kind permission from Harkness et al.
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Nonsustained Ventricular Tachycardia November 13, 2012:1993–2004dicted SCD only in patients with LVEF 35%. No Holter
variable was predictive of outcome in the presence of LVEF
35% (69). In the modern era, only the ATRAMI (Auto-
nomic Tone and Reflexes After Myocardial Infarction) trial
(1,071 post-MI patients) found NSVT to be an indepen-
dent predictor of adverse prognosis (61). Recently, the
CARISMA (Cardiac Arrhythmias and Risk Stratification
After Acute Myocardial Infarction) Study Group (2) re-
ported on long-term cardiac arrhythmias recorded by a
cardiac monitor implanted 2 to 5 days after MI in 297
patients with LVEF 40%. NSVT (VT 125 beats/min
or 16 beats lasting 30 s) was the most frequent
entricular arrhythmia recorded in the study (incidence of
3%) but was not associated with cardiac death over the
ext 2 years in multivariate analysis. With reperfusion
nd use of beta-blockers, therefore, NSVT after MI may
ot be an independent predictor of mortality, especially
fter EF is taken into account, and its prognostic signif-
cance is ambiguous.
ther clinical settings. The circumstances under which
SVT occurs are of clinical importance. MUSTT (Multi-
enter Unsustained Tachycardia Trial) data have shown a
orse prognosis in patients with out-of-hospital, as opposed
o in-hospital, identified NSVT (70). In patients subjected
o surgical coronary revascularization, the occurrence of
SVT within the early (10 days) post-revascularization
eriod is associated with a far better outcome than when it
ccurs later after coronary artery bypass graft or in non–
ost-operative settings (71). However, when sustained VT
s inducible in patients with early post-operative NSVT, the
utcome is worse compared with that for noninducible
atients (72). In the MUSTT study, racial differences were
Figure 4 NSVT in a Patient With a
Previous Small Anteroseptal Infarct
This is monomorphic NSVT (left bundle branch block–like morphology)
most probably related to the septal scar. Abbreviation as in Figure 1.lso shown to influence outcome of patients with NSVT Nnd reduced LV function (73). Few recent data on patients
ith stable IHD and LVEF 40% exist.
linical assessment of ischemic patients with NSVT.
ests of ischemia are mandatory. Acute myocardial isch-
mia is an established cause of polymorphic ventricular
hythms (64). The association of monomorphic NSVT, a
ubstrate-dependent arrhythmia, with acute ischemia is less
ell characterized, but ischemia may induce sustained or
onsustained monomorphic VT in the presence of a myo-
ardial scar (74,75).
Echocardiography may detect signs of cardiomyopathy or
ther structural abnormalities and impaired LV function.
here has been overwhelming evidence that in patients
ith heart disease in general, LVEF is the major deter-
inant of cardiac and total mortality (3,4,76). However,
VEF does not always predict ICD intervention in
atients with ischemic or nonischemic cardiomyopathy
77), and analysis of arrhythmic death in 674 patients
nrolled in the MUSTT study showed that patients
hose only risk factor was EF 30% had a predicted
-year arrhythmic death risk 5% (78).
Holter monitoring is a valuable diagnostic tool for de-
ecting patients with NSVT, and 7-day Holter monitoring
mproves the detection of ventricular arrhythmic episodes
79). However, the suppression of frequent ventricular
ctopy or NSVT runs with antiarrhythmic drugs does not
mply a favorable diagnosis (80) and may increase mortality
81,82). Thus, Holter monitoring may be useful for risk
tratification purposes by means of detecting episodes of
SVT in certain clinical settings, but its use for the
ubsequent follow-up and evaluation of treatment is limited.
The major utility of EPS testing in patients with NSVT
nd IHD is for LVEF between 30% and 40%. In NSVT in
he context of reduced LVEF (40%), inducibility of
ustained monomorphic VT at baseline EPS was associated
ith a 2-year actuarial risk of sudden death or cardiac arrest
f 50% compared with a 6% risk in patients without
nducible VT (83). Noninducible patients in the MUSTT
tudy had a significantly lower risk of cardiac arrest or
udden death compared with inducible patients at 2 and 5
ears (12% vs. 24% and 18% vs. 32%, respectively) (84), and
he higher percentage of events that were arrhythmic among
atients with inducible tachyarrhythmia appeared more
istinct among patients with an EF 30% (61% of events
ere arrhythmic among inducible and only 42% among
oninducible patients, p  0.002) (85).
The results of the ATRAMI trial (61) regarding the
rognostic significance of heart rate variability have not
een reproduced by other studies (86–88), and autonomic
arkers, as well as signal-averaged ECG, in the beta-
locking era have limited predictive power in identifying
atients at risk of SCD (89). Promising results on the
redictive ability of T-wave alternans tests have not been
onsistent (90–92). In patients with LVEF 40% and
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November 13, 2012:1993–2004 Nonsustained Ventricular TachycardiaEPS, or both might identify subsets of patients least likely
to benefit from ICD insertion (93).
Therapy of ischemic patients with NSVT. The treatment
of ischemic patients with NSVT should first include mod-
ern therapy for IHD, such as revascularization, beta-
blockers, statins, and angiotensin II receptor blockers or
angiotensin-converting enzyme inhibitors. Revasculariza-
tion and beta-blockade seem to be especially important in
acute coronary syndromes in this respect (57). Flecainide
(81,82) and sotalol (94) increase mortality, whereas ami-
odarone shows a trend toward reducing arrhythmia epi-
sodes but without significantly affecting total mortality
(95,96) or even showing a trend toward increasing it (97).
Therefore, no antiarrhythmic drug is suitable for primary
prevention of cardiac death with exception for beta-
blockers, which were shown in several studies to reduce
total and cardiac mortality in post-infarction patients, at
least during the first year post-MI (98). There are no data
indicating that NSVT in post-infarction patients with
EF 40% requires specific antiarrhythmic therapy apart
from beta-blockade. The role of EPS-guided therapy in
these patient populations remains to be determined.
Patients presenting with syncope and with inducible VF,
or especially monomorphic VT, should be considered for
ICD in the absence of reversible ischemia (Table 1).
LV Dysfunction and Heart Failure
In patients with ischemic and nonischemic heart failure and
LVEF 30% to 40%, the reported prevalence of NSVT is
30% to 80% (99,100). In dilated cardiomyopathy, NSVT
has been detected in 40% to 50% of patients (101–103). In
approximately 10% of the cases of idiopathic dilated cardio-
myopathy, sustained or nonsustained VT is due to bundle
branch re-entry (104). These tachycardias are usually unsta-
ble, and the 12-lead ECG may show either LBBB or RBBB
pattern.
No convincing data on the predictive ability of NSVT
exist in patients with heart failure. The GESICA-GEMA
(Grupo de Estudio de la Sobrevida en la Insuficiencia
Cardiaca en Argentina–Grupo de Estudios Multicéntricos
en Argentina) investigators identified NSVT as an indepen-
dent predictor of total mortality in 516 patients with heart
failure (35% to 40% IHD) and LVEF 35% (99); NSVT
detected on Holter monitoring and lack of use of beta-
blockers, but not LVEF, have been found predictive for
ICD-derived arrhythmias in patients with ischemic or
nonischemic cardiomyopathy (77). However, after adjust-
ment for other variables and especially for LVEF, NSVT
was not an independent predictor of sudden death or total
mortality in 674 patients with heart failure and LVEF
35% to 50% (70% to 75% IHD) who were enrolled in the
CHF STAT (Survival Trial of Antiarrhythmic Therapy in
Congestive Heart Failure) (80,100). Similar results were
published by the PROMISE (Prospective Randomized
Milrinone Survival Evaluation) investigators; 1,080 patients wwith New York Heart Association class III/IV symptoms
and LVEF 35% were enrolled in the PROMISE study
5). Only during the recovery period after exercise has
requent ventricular ectopy been found to carry an adverse
rognostic significance in patients with heart failure (105).
here is also no consistency in reports investigating the
ssociation between NSVT and cardiac mortality in series
ith nonischemic dilated cardiomyopathy only. In the
arburg cardiomyopathy study, arrhythmia risk stratifica-
ion was performed on 343 patients with dilated cardiomyo-
athy (3). On multivariate analysis, only LVEF was found
o be a significant predictor of major arrhythmic events,
ith a relative risk of 2.3 per 10% decrease of EF. However,
atients with NSVT in the context of LVEF 30% had an
-fold arrhythmia risk compared with patients with LVEF
30% without NSVT (3). Recently, LVEF, NSVT, and
teeper QTe slope (assessed by dedicated software) were
ound to be significant predictors of arrhythmic events
106). Interestingly, after medical stabilization with
ngiotensin-converting enzyme inhibitors and beta-
lockers, the number and length of NSVT runs did not
ncrease the risk of major ventricular arrhythmias in
atients with LVEF 35% as opposed to those with
VEF 35% (107).
linical assessment and therapy. The most useful risk
tratifier is still LVEF despite its limitations, and recom-
endations for ICD are mainly based on LVEF and
ymptomatic status of heart failure. In ischemic patients,
rogrammed stimulation is indicated in the presence of
SVT when LVEF is 30% to 40%, as previously discussed.
he prognostic usefulness of programmed stimulation in
atients with nonischemic dilated cardiomyopathy, in-
luding those with NSVT, remains controversial (108,109).
here has been some evidence that inducibility of ventricular
rrhythmias (110) and especially polymorphic VT or VF (111)
ndicates increased likelihood of subsequent ICD therapies and
ight be considered a useful risk stratifier. In patients with
onischemic cardiomyopathy, signal-averaged ECG does not
redict sudden death (3), and results on the value of heart rate
ariability have also been conflicting (112,113).
Amiodarone therapy was associated with decreased mor-
ality in the GESICA trial (97), whereas no such effect was
bserved in the CHF-STAT trial (80) or the SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial) (114).
ronedarone also did not fulfill hopes regarding its preven-
ion of mortality in patients with heart failure (115). Certain
atients with NSVT in the context of reduced LV function
eed an ICD, as has been demonstrated in the MADIT
Multicenter Automatic Defibrillator Implantation Trial)
116), MUSTT (117), MADIT II (118), and SCD-Heft
114) trials (Table 1). ICDs, however, should be considered
40 days after MI to achieve reduction of total mortality
119,120).
Although according to the SCD-Heft study, patients
ith symptomatic heart failure and LVEF35% are treated
ith ICD with or without additional cardiac resynchroni-
2000 Katritsis et al. JACC Vol. 60, No. 20, 2012
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nonischemic dilated cardiomyopathy with (121,122) or
without (123) NSVT is debatable. No single trial has
demonstrated a reduction in total (as opposed to arrhyth-
mic) mortality in this setting.
Hypertrophic Cardiomyopathy
There is no characteristic ECG morphology of NSVT in
patients with HCM. Up to 20% to 30% of patients may
have NSVT, whereas this proportion approaches 80% in
patients with a history of cardiac arrest (124–126). Rela-
tively slow, often asymptomatic NSVT episodes may be
documented on prolonged ambulatory recordings. When
nonsustained or sustained VT is induced by programmed
stimulation, it is more often polymorphic than monomor-
phic (126). However, these estimations may not reflect the
true incidence of NSVT in HCM because they are based on
highly selected referral populations. In patients with HCM,
the presence of delayed enhancement on contrast-enhanced
MRI (127) or of echocardiographic 2-dimensional strain,
which is used to identify myocardial fibrosis, in more than
3 LV segments (128) is associated with increased likeli-
hood of NSVT. Frequent and prolonged (10 beats)
episodes of nonsustained VT on Holter monitoring most
probably indicate an increased risk of sudden death in
HCM, especially in young patients (125). Recent MRI
studies support this notion. NSVT was reported in 31%
of 178 patients with HCM; for sudden death, NSVT had
negative and positive predictive values of 95% and 9% and
sensitivity and specificity of 45% and 69%, respectively
(129). In another report, NSVT, but not myocardial
fibrosis, was an independent predictor of arrhythmic
events and death (130).
Beta-blockers may decrease the risk of sudden death, but
defibrillator implantation is the therapy of choice in the
presence of high-risk factors, including frequent NSVT
accompanied by history of syncope or family history of
sudden death at young age, may justify defibrillator implan-
tation as primary prevention in patients with HCM (131).
Arrhythmogenic Right
Ventricular Cardiomyopathy
The tachycardias in ARVC arise from the right ventricle
and typically present with LBBB morphology with a left or
even right axis deviation (132).
Patients with ARVC may present with asymptomatic
NSVT despite only subtle RV abnormalities and have a
trend for an increased arrhythmic risk and a rate of appro-
priate ICD intervention of 3.7% per year (133). The results
of antiarrhythmic medications are disappointing, and ICD
seems to be the therapy of choice in patients with cardiac
arrest, syncope, or hemodynamically poorly tolerated VT
despite antiarrhythmic therapy. Catheter ablation of VT
when feasible is successful in reducing further episodes but
cannot offer absolute protection without ICD backup (134).Other Conditions
Giant-cell myocarditis is a cause of monomorphic or poly-
morphic VT that is usually sustained and associated with
high mortality (135). Ventricular extrasystolic activity can
be detected with Holter monitoring in up to 50% of patients
with repaired tetralogy of Fallot, and recent studies have
detected a 4% to 14% prevalence of sustained VT (136–138).
Inducible sustained monomorphic or polymorphic VT is an
independent risk factor for subsequent events in patients
with repaired tetralogy of Fallot (137). Complex ventricular
arrhythmias are common in AL amyloidosis (57% of pa-
tients have PVCs and 18% NSVT) and carry prognostic
significance (139). Cardiac sarcoidosis may present with
nonsustained polymorphic or monomorphic VT that usually
responds to steroids. Development of sustained monomor-
phic VT is an ominous sign, and ICD may be indicated
(140). Patients with Chagas cardiomyopathy presenting
with either sustained VT or NSVT have a major risk for
mortality in the presence of moderate LV systolic dysfunc-
tion (LVEF 40%) (141). In patients with tachycardiopa-
thy, the presence of NSVT, in addition to the PVC burden,
longer PVC duration, multiform PVCs, and RV PVCs,
may be associated with the development of cardiomyopathy
(142). Eradication of the arrhythmia may result in restora-
tion of LV function.
Conclusions
NSVT can be recorded in a wide range of conditions, in
apparently healthy individuals to patients with significant
heart disease. Its prognostic significance varies, depending
on the underlying condition, and in several clinical settings
is not known. The management of patients with NSVT is
aimed at treating the underlying heart disease rather than
the arrhythmia itself, unless serious symptoms occur.
Reprint requests and correspondence: Dr. Demosthenes Katritsis,
Athens Euroclinic, 9 Athanassiadou Street, Athens 11521,
Greece. E-mail: dkatritsis@euroclinic.grdgkatr@otenet.gr.
REFERENCES
1. Katritsis DG, Camm AJ. Nonsustained ventricular tachycardia:
where do we stand? Eur Heart J 2004;25:1093–9.
2. Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term
recording of cardiac arrhythmias with an implantable cardiac monitor
in patients with reduced ejection fraction after acute myocardial
infarction: the Cardiac Arrhythmias and Risk Stratification After
Acute Myocardial Infarction (CARISMA) study. Circulation 2010;
122:1258–64.
3. Grimm W, Christ M, Bach J, Müller HH, Maisch B. Noninvasive
arrhythmia risk stratification in idiopathic dilated cardiomyopathy:
results of the Marburg cardiomyopathy study. Circulation 2003;108:
2883–91.
4. Caruso AC, Marcus FI, Hahn EA, Hartz VL, Mason JW. Predictors
of arrhythmic death and cardiac arrest in the ESVEM trial. Electro-
physiologic Study Versus Electromagnetic Monitoring. Circulation
1997;96:1888–92.
5. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular
arrhythmias in patients with heart failure do not specifically predict
2001JACC Vol. 60, No. 20, 2012 Katritsis et al.
November 13, 2012:1993–2004 Nonsustained Ventricular Tachycardiaan increased risk of sudden death. PROMISE (Prospective
Randomized Milrinone Survival Evaluation) Investigators. Circula-
tion 2000;101:40–6.
6. Senges JC, Becker R, Schreiner KD, et al. Variability of Holter
electrocardiographic findings in patients fulfilling the noninvasive
MADIT criteria. Multicenter Automatic Defibrillator Implantation
Trial. Pacing Clin Electrophysiol 2002;25:183–90.
7. Bikkina M, Larson MG, Levy D. Prognostic implications of asymp-
tomatic ventricular arrhythmias: the Framingham heart study. Ann
Int Med 1992;117:990–6.
8. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhyth-
mias and mortality risk in subjects with left ventricular hypertrophy.
J Am Coll Cardiol 1993;22:1111–6.
9. Engstrom G, Hedblad B, Janzon L, et al. Ventricular arrhythmias
during 24-h ambulatory ECG recording: incidence, risk factors and
prognosis in men with and without a history of cardiovascular disease.
J Intern Med 1999;246:363–72.
10. Jouven X, Zureik M, Desnos M, Courbon D, Ducimetiere P.
Long-term outcome in asymptomatic men with exercise-induced
premature ventricular depolarizations. N Engl J Med 2000;343:
826 –33.
11. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent
ventricular ectopy after exercise as a predictor of death. N Engl
J Med. 2003;348:781–90.
12. Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance
of frequent and complex ventricular tachyarrhythmias in trained
athletes. J Am Coll Cardiol 2002;40:446–52.
13. Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease
and arrhythmias in the long-term follow-up of former professional
cyclists. Eur Heart J 2008;29:71–8.
14. Biffi A, Maron BJ, Di Giacinto B, et al. Relation between training-
induced left ventricular hypertrophy and risk for ventricular tachyar-
rhythmias in elite athletes. Am J Cardiol 2008;101:1792–5.
15. Biffi A, Maron BJ, Verdile L, et al. Impact of physical deconditioning
on ventricular tachyarrhythmias in trained athletes. J Am Coll
Cardiol 2004;44:1053–8.
16. Biffi A, Maron BJ, Culasso F, et al. Patterns of ventricular tachyar-
rhythmias associated with training, deconditioning and retraining in
elite athletes without cardiovascular abnormalities. Am J Cardiol
2011;107:697–703.
17. Surawicz B, Macfarlane PW. Inappropriate and confusing electro-
cardiographic terms J-wave syndromes and early repolarization. J Am
Coll Cardiol 2011;57:1584–6.
18. Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010;7:
549–58.
19. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome
associated with early repolarization on electrocardiography. N Engl
J Med 2009;361:2529–37.
20. Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest
associated with early repolarization. N Engl J Med 2008;358:
2016 –23.
21. Watanabe H, Makiyama T, Koyama T, et al. High prevalence of
early repolarization in short QT syndrome. Heart Rhythm 2010;7:
647–52.
22. Cappato R, Furlanello F, Giovinazzo V, et al. J wave, QRS slurring,
and ST elevation in athletes with cardiac arrest in the absence of heart
disease: marker of risk or innocent bystander? Circ Arrhythm
Electrophysiol 2010;3:305–11.
23. Tikkanen JT, Junttila MJ, Anttonen O, et al. Early repolarization:
electrocardiographic phenotypes associated with favorable long-term
outcome. Circulation 2011;123:2666–73.
24. Lehnart SE, Ackerman MJ, Benson DW Jr., et al. Inherited
arrhythmias: a National Heart, Lung, and Blood Institute and Office
of Rare Diseases workshop consensus report about the diagnosis,
phenotyping, molecular mechanisms, and therapeutic approaches for
primary cardiomyopathies of gene mutations affecting ion channel
function. Circulation 2007;116:2325–45.
25. Katritsis D, Gill J, Camm AJ. Repetitive monomorphic ventricular
tachycardia. In: Zipes DP, Jalife J, editors: Clinical Electrophysiol-
ogy: From Cell to Bedside. 2nd edition. Philadelphia, PA: Saunders,
1995:900–6.
26. Kim RJ, Iwai S, Markowitz SM, Shah BK, Stein KM, Lerman BB.
Clinical and electrophysiological spectrum of idiopathic ventricular
outflow tract arrhythmias. J Am Coll Cardiol 2007;49:2035–43.27. Buxton AE, Marschlinski FE, Doherty JU, et al. Repetitive mono-
morphic ventricular tachycardia: clinical and electrophysiologic char-
acteristics in patients with and patients without organic heart disease.
Am J Cardiol 1984;54:997–1002.
28. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic
ventricular tachycardia originating from the aortic sinus cusp: elec-
trocardiographic characterization for guiding catheter ablation. J Am
Coll Cardiol 2002;39:500–8.
29. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia: proposed mod-
ification of the Task Force Criteria. Eur Heart J 2010;31:806–14.
30. Carlson MD, White RD, Trohman RG, et al. Right ventricular
outflow tract ventricular tachycardia: detection of previously unrec-
ognized anatomic abnormalities using cine magnetic resonance im-
aging. J Am Coll Cardiol 1994;24:720–7.
31. Chimenti C, Calabrese F, Thiene G, Pieroni M, Maseri A, Frustaci
A. Inflammatory left ventricular microaneurysms as a cause of
apparently idiopathic ventricular tachyarrhythmias. Circulation 2001;
104:168–73.
32. Hoffmayer KS, Machado ON, Marcus GM, et al. Electrocardio-
graphic comparison of ventricular arrhythmias in patients with
arrhythmogenic right ventricular cardiomyopathy and right ventric-
ular outflow tract tachycardia. J Am Coll Cardiol 2011;58:831–8.
33. Shimizu W. Arrhythmias originating from the right ventricular
outflow tract: how to distinguish “malignant” from “benign”? Heart
Rhythm 2009;6:1507–11.
34. Blanck Z, Jazayeri M, Dhala A, Deshpande S, Sra J, Akhtar M.
Bundle branch reentry: a mechanism of ventricular tachycardia in the
absence of myocardial or valvular dysfunction. J Am Coll Cardiol
1993;22:1718–22.
35. Katritsis D, Ahsan A, Anderson M, et al. Catheter ablation for
successful management of fascicular tachycardia. An approach guided
by the recording of fascicular potentials. Heart 1996;75:384–8.
36. Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of
idiopathic left ventricular tachycardia: unidirectional block and mac-
roreentry within the Purkinje network. Circulation 2002;105:462–9.
37. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhyth-
mic effects of flecainide acetate and encainide hydrochloride by
propranolol. Circulation 1989;80:1571–9.
38. Stevenson WG, Soejima K. Catheter ablation for ventricular tachy-
cardia. Circulation 2007;115:2750–60.
39. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome:
report of the second consensus conference: endorsed by the Heart
Rhythm Society and the European Heart Rhythm Association.
Circulation 2005;111:659–70.
40. Zareba W, Moss AJ, le Cessie S, et al. Risk of cardiac events in long
QT syndrome family members. J Am Coll Cardiol 1995;26:1685–91.
41. Morita H, Wu J, Zipes DP. The QT syndromes: long and short.
Lancet 2008;372:750–63.
42. Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche
P, Coumel P. Short-coupled variant of torsade de pointes: a new
electrocardiographic entity in the spectrum of idiopathic ventricular
tachyarrhythmias. Circulation 1993;89:206–15.
43. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in
high-risk patients with the congenital long-QT syndrome types 1 and
2: implications for patient management. J Cardiovasc Electrophysiol
2010;21:893–901.
44. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT
syndrome loci and cardiac events among patients treated with
beta-blockers. JAMA 2004;292:1341–4.
45. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT
syndrome patients who receive an implantable cardioverter-
defibrillator and what happens to them?: data from the European
Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS
ICD) registry. Circulation 2010;122:1272–82.
46. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization
and long-term outcomes in catecholaminergic polymorphic ventric-
ular tachycardia. Heart Rhythm 2011;8:864–71
47. Horner JM, Ackerman MJ. Ventricular ectopy during treadmill
exercise stress testing in the evaluation of long QT syndrome. Heart
Rhythm 2008;5:1690–4.
48. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel blockers
and beta-blockers versus beta-blockers alone for preventing exercise-
2002 Katritsis et al. JACC Vol. 60, No. 20, 2012
Nonsustained Ventricular Tachycardia November 13, 2012:1993–2004induced arrhythmias in catecholaminergic polymorphic ventricular
tachycardia. Heart Rhythm 2007;4:1149–54.
49. European Heart Rhythm Association, Heart Rhythm Society, Zipes
DP, et al. ACC/AHA/ESC 2006 guidelines for management of
patients with ventricular arrhythmias and the prevention of sudden
cardiac death: a report of the American College of Cardiology/
American Heart Association Task Force and the European Society of
Cardiology Committee for Practice Guidelines (Writing Committee
to Develop Guidelines for Management of Patients With Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death). J Am
Coll Cardiol 2006;48:e247–346.
50. McLenaghan JM, Henderson E, Morris KI, Dargie HJ. Ventricular
arrhythmias in patients with hypertensive left ventricular hypertro-
phy. N Engl J Med 1987;317:787–92.
51. Pringle SD, Dunn FG, Macfarlane PW, McKillop JH, Lorimer AR,
Cobbe SM. Significance of ventricular arrhythmias in systemic
hypertension with left ventricular hypertrophy. Am J Cardiol 1992;
69:913–7.
52. Martinez-Rubio A, Schwammenthal Y, Schwammenthal E, et al.
Patients with valvular heart disease presenting with sustained ven-
tricular tachyarrhythmias and syncope. Results of programmed ven-
tricular stimulation and long-term follow-up. Circulation 1997;96:
500–8.
53. Kilgfield P, Levy D, Devreux RB, Savage DD. Arrhythmias and
sudden death in mitral valve prolapse. Am Heart J 1987;113:1298–
307.
54. Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in
mitral regurgitation due to flail leaflet. J Am Coll Cardiol 1999;34:
2078–85.
55. Avierinos JF, Gersh BJ, Melton LJ III, et al. Natural history of
asymptomatic mitral valve prolapse in the community. Circulation
2002;106:1355–61.
56. Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between
nonsustained ventricular tachycardia after non-ST-elevation acute
coronary syndrome and sudden cardiac death: observations from the
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-
ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocar-
dial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
Circulation 2010;122:455–62.
57. Harkness JR, Morrow DA, Braunwald E, et al. Myocardial ischemia
and ventricular tachycardia on continuous electrocardiographic mon-
itoring and risk of cardiovascular outcomes after non-ST-segment
elevation acute coronary syndrome (from the MERLIN-TIMI 36
trial). Am J Cardiol 2011;108:1373–81.
58. Heidbüchel H, Tack J, Vanneste L, Ballet A, Ector H, Van de Werf
F. Significance of arrhythmias during the first 24 hours of acute
myocardial infarction treated with alteplase and effect of early
administration of a beta-blocker or a bradycardiac agent on their
incidence. Circulation 1994;89:1051–9.
59. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and
prognostic significance of ventricular arrhythmias after acute myocar-
dial infarction in the fibrinolytic era: GISSI-2 results. Circulation
1993;87:312–22.
60. Hohnloser SH, Klingenheben T, Zabel M, et al. Prevalence, char-
acteristics and prognostic value during long-term follow-up of non-
sustained ventricular tachycardia after myocardial infarction in the
thrombolytic era. J Am Coll Cardiol 1999;33:1895–902.
61. La Rovere MT, Pinna GD, Hohnloser SH, et al. Autonomic tone
and reflexes after myocardial infarction. Baroreflex sensitivity and
heart rate variability in the identification of patients at risk for
life-threatening arrhythmias: implications for clinical trials. Circula-
tion 2001;103:2072–7.
62. Høfsten DE, Wachtell K, Lund B, Mølgaard H, Egstrup K.
Prevalence and prognostic implications of non-sustained ventricular
tachycardia in ST-segment elevation myocardial infarction after
revascularization with either fibrinolysis or primary angioplasty. Eur
Heart J 2007;28:407–14.
63. Bigger JT Jr., Fleiss JL, Rolnitzky LM. Prevalence, characteristics
and significance of ventricular tachycardia detected by 24-hour
continuous electrocardiographic recordings in the late hospital phase
of acute myocardial infarction. Am J Cardiol 1986;58:1151–60.
64. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M.
Polymorphous ventricular tachycardia associated with acute myocar-
dial infarction. Circulation 1991;84:1543–51.65. Di Bella G, Passino C, Aquaro GD, et al. Different substrates of
non-sustained ventricular tachycardia in post-infarction patients with
and without left ventricular dilatation. J Card Fail 2010;16:61–8.
66. Cheema AN, Sheu K, Parker M, Kadish AH, Goldberger JJ.
Nonsustained ventricular tachycardia in the setting of acute myocar-
dial infarction: tachycardia characteristics and their prognostic impli-
cations. Circulation 1998;98:2030–6.
67. Multicenter Post-Infarction Research Group. Risk stratification and
survival after myocardial infarction. N Engl J Med 1983;309:331–6.
68. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death
after acute myocardial infarction: two-year follow-up. Am J Cardiol
1984;54:31–6.
69. Makikallio TH, Barthel P, Schneider R, et al. Prediction of sudden
cardiac death after acute myocardial infarction: role of Holter
monitoring in the modern treatment era. Eur Heart J 2005;26:762–9.
70. Pires LA, Lehmann MH, Buxton AE, Hafley GE, Lee KL. The
Multicenter Unsustained Tachycardia Trial Investigators. Differences
in inducibility and prognosis of in-hospital versus out-of-hospital
identified nonsustained ventricular tachycardia in patients with cor-
onary artery disease: clinical and trial design implications. J Am Coll
Cardiol 2001;38:1156–62.
71. Pires LA, Hafley GE, Lee KL, et al. Prognostic significance of
nonsustained ventricular tachycardia after coronary bypass surgery in
patients with left ventricular dysfunction. J Cardiovasc Electrophysiol
2002;13:757–63.
72. Mittal S, Lomnitz DJ, Mirchandani S, et al. Prognostic significance
of nonsustained ventricular tachycardia after revascularization. J Car-
diovasc Electrophysiol 2002;13:342–6.
73. Russo AM, Hafley GE, Lee KL, et al. Racial differences in outcome
in the Multicenter Unsustained Tachycardia Trial (MUSTT): a
comparison of whites versus blacks. Circulation 2003;108:67–72.
74. Furukawa T, Moroe K, Mayrovitz HN, Sampsell R, Myerburg RJ.
Arrhythmogenic effects of graded coronary blood flow reduction
superimposed upon prior myocardial infarction in dogs. Circulation
1991;84:368–77.
75. Garan H, McComb JM, Ruskin JN. Spontaneous and electrically
induced ventricular arrhythmias during acute ischemia superimposed
on 2 week old canine myocardial infarction. J Am Coll Cardiol
1988;11:603–11.
76. Camm AJ, Katritsis D. Risk stratification of patients with ventricular
arrhythmias. In: Zipes DP, Jalife J, editors: Clinical Electrophysiol-
ogy: From Cell to Bedside. 3rd edition. Philadelphia, PA: Saunders,
2000:808–27.
77. Verma A, Sarak B, Kaplan AJ, et al. Predictors of appropriate
implantable cardioverter defibrillator (ICD) therapy in primary pre-
vention patients with ischemic and nonischemic cardiomyopathy.
Pacing Clin Electrophysiol 2010;33:320–9.
78. Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection
fraction for prediction of sudden death risk in patients with coronary
artery disease: lessons from the MUSTT study. J Am Coll Cardiol
2007;50:1150–7.
79. Pastor-Pérez FJ, Manzano-Ferna´ndez S, Goya-Esteban R, et al.
Comparison of detection of arrhythmias in patients with chronic
heart failure secondary to non-ischemic versus ischemic cardiomyo-
pathy by 1 versus 7-day Holter monitoring. Am J Cardiol 2010;106:
677–81.
80. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients
with congestive heart failure and asymptomatic ventricular arrhyth-
mia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart
Failure. N Engl J Med 1995;333:77–82.
81. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Pre-
liminary report: effect of encainide and flecainide on mortality in a
randomized trial of arrhythmia suppression after myocardial infarc-
tion. N Engl J Med 1989;321:406–12.
82. Cardiac Arrhythmia Suppression Trial-II Investigators. Effect of
antiarrhythmic agent moricizine on survival after myocardial infarc-
tion. The Cardiac Arrhythmia Suppression Trial-II. N Engl J Med
1992;327:227–33.
83. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological
testing and nonsustained ventricular tachycardia. Use and limitations
in patients with coronary artery disease and impaired ventricular
function. Circulation 1990;82:350–8.
84. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to
























2003JACC Vol. 60, No. 20, 2012 Katritsis et al.
November 13, 2012:1993–2004 Nonsustained Ventricular Tachycardiadeath. Multicenter Unsustained Tachycardia Trial Investigators. N Engl
J Med 2000;342:1937–45.
85. Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction
and inducible ventricular tachycardia to mode of death in patients
with coronary artery disease: an analysis of patients enrolled in the
Multicenter Unsustained Tachycardia Trial. Circulation 2002;106:
2466–72.
86. Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of
sudden cardiac death after myocardial infarction in the beta-blocking
era. J Am Coll Cardiol 2003;42:652–8.
87. Abildstrom SZ, Jensen BT, Agner E, et al. Heart rate versus heart
rate variability in risk prediction after myocardial infarction. J Car-
diovasc Electrophysiol 2003;14:168–73.
88. Bauer A, Guzik P, Barthel P, et al. Reduced prognostic power of
ventricular late potentials in post-infarction patients of the reperfu-
sion era. Eur Heart J 2005;26:755–61.
89. Stein KM. Noninvasive risk stratification for sudden death: signal-
averaged electrocardiography, nonsustained ventricular tachycardia,
heart rate variability, baroreflex sensitivity, and QRS duration. Prog
Cardiovasc Dis 2008;51:106–17.
90. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt
T-wave alternans distinguishes between patients likely and patients
not likely to benefit from implanted cardiac defibrillator therapy: a
solution to the Multicenter Automatic Defibrillator Implantation
Trial (MADIT) II conundrum. Circulation 2004;110:1885–9.
91. Amit G, Rosenbaum DS, Super DM, Costantini O. Microvolt
T-wave alternans and electrophysiologic testing predict distinct
arrhythmia substrates: implications for identifying patients at risk for
sudden cardiac death. Heart Rhythm 2010;7:763–8.
92. Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave
alternans testing predict ventricular tachyarrhythmias in patients with
ischemic cardiomyopathy and prophylactic defibrillators? The
MASTER (Microvolt T Wave Alternans Testing for Risk Stratifi-
cation of Post-Myocardial Infarction Patients) trial. J Am Coll
Cardiol 2008;52:1607–15.
93. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alter-
nans Before Cardioverter Defibrillator) trial: strategies using T-wave
alternans to improve efficiency of sudden cardiac death prevention.
J Am Coll Cardiol 2009;53:471–9.
94. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on
mortality in patients with left ventricular dysfunction after recent and
remote myocardial infarction. The SWORD Investigators. Survival
With Oral d-Sotalol. Lancet 1996;348:7–12.
95. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction
mortality in patients with ventricular premature depolarizations.
Circulation 1991;84:550–7.
96. Julian DG, Camm AJ, Frangin J, et al. Randomised trial of effect of
amiodarone on mortality in patients with left ventricular dysfunction
after recent myocardial infarction: EMIAT. Lancet 1997;349:662–3.
97. Elizari MV, Martı´nez JM, Belziti C, et al. Morbidity and mortality
following early administration of amiodarone in acute myocardial
infarction. GEMICA Study Investigators, GEMA Group, Buenos
Aires, Argentina. Grupo de Estudios Multicéntricos en Argentina.
Eur Heart J 2000;21:198–205.
98. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial
infarction: influence of first-year clinical course on long-term effec-
tiveness. Ann Intern Med 1993;118:99–105.
99. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular
tachycardia in severe heart failure. Independent marker of increased
mortality due to sudden death. GESICA-GEMA Investigators.
Circulation 1996;94:3198–203.
00. Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and
significance of nonsustained ventricular tachycardia in patients with
premature ventricular contractions and heart failure treated with
vasodilator therapy. J Am Coll Cardiol 1998;32:942–7.
01. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular
arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol
1984;53:902–7.
02. Neri R, Mestroni L, Salvi A, Camerini F. Arrhythmias in dilated
cardiomyopathy. Postgrad Med J 1986;62:593–7.
03. Olshausen KV, Stienen U, Schwartz F, et al. Long-term prognostic
significance of ventricular arrhythmias in idiopathic dilated cardio-
myopathy. Am J Cardiol 1988;61:146–51.04. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein
LM. Endocardial and epicardial radiofrequency ablation of ventric-
ular tachycardia associated with dilated cardiomyopathy: the impor-
tance of low-voltage scars. J Am Coll Cardiol 2004;43:1834–42.
05. O’Neill JO, Young JB, Pothier CE, et al. Severe frequent ventricular
ectopy after exercise as a predictor of death in patients with heart
failure. J Am Coll Cardiol 2004;44:820–6.
06. Iacoviello M, Forleo C, Guida P, et al. Ventricular repolarization
dynamicity provides independent prognostic information toward
major arrhythmic events in patients with idiopathic dilated cardio-
myopathy. J Am Coll Cardiol 2007;50:225–31.
07. Zecchin M, Di Lenarda A, Gregori D, et al. Are nonsustained
ventricular tachycardias predictive of major arrhythmias in patients
with dilated cardiomyopathy on optimal medical treatment? Pacing
Clin Electrophysiol 2008;31:290–9.
08. Grimm W, Hoffmann J, Menz V, et al. Programmed ventricular
stimulation for arrhythmia risk prediction in patients with idiopathic
dilated cardiomyopathy and nonsustained ventricular tachycardia.
J Am Coll Cardiol 1998;32:739–45.
09. Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed
ventricular stimulation and implantable cardioverter defibrillators in
patients with idiopathic dilated cardiomyopathy and syncope. Pacing
Clin Electrophysiol 2001;24:1623–30.
10. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia
inducibility predicts subsequent ICD activation in nonischemic
cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Elec-
trophysiol 2009;32:755–61.
11. Rolf S, Haverkamp W, Borggrefe M, Breithardt G, Bocker D.
Induction of ventricular fibrillation rather than ventricular tachycar-
dia predicts tachyarrhythmia recurrences in patients with idiopathic
dilated cardiomyopathy and implantable cardioverter defibrillator for
secondary prophylaxis. Europace 2009;11:289–96.
12. Fauchier L, Babuty D, Cosnay P, et al. Prognostic value of heart rate
variability for sudden death and major arrhythmic events in patients
with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1999;33:
1203–7.
13. Rashba EJ, Estes NA, Wang P, et al. Preserved heart rate variability
identifies low-risk patients with nonischemic dilated cardiomyopathy:
results from the DEFINITE trial. Heart Rhythm 2006;3:281–6.
14. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure. N Engl J Med
2005;352:225–37.
15. Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality
after dronedarone therapy for severe heart failure. N Engl J Med
2008;358:2678–87.
16. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high risk
for ventricular arrhythmia. Multicenter Automatic Defibrillator Im-
plantation Trial Investigators. N Engl J Med 1996;335:1933–40.
17. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the
prevention of sudden death in patients with coronary artery disease.
Multicenter Unsustained Tachycardia Trial Investigators. N Engl
J Med 1999;341:1882–90.
18. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of
primary prevention with an implantable cardioverter-defibrillator: an
extended 8-year follow-up study of the Multicenter Automatic
Defibrillator Implantation Trial II. Circulation 2010;122:1265–71.
19. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an
implantable cardioverter-defibrillator after acute myocardial infarc-
tion. N Engl J Med 2004;351:2481–8.
20. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation
early after myocardial infarction. N Engl J Med 2009;361:1427–36.
21. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator
implantation in patients with nonischemic dilated cardiomyopathy.
N Engl J Med 2004;350:2151–7.
22. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus
implantable cardioverter-defibrillator:randomized trial in patients
with nonischemic dilated cardiomyopathy and asymptomatic nonsus-
tained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol
2003;41:1707–12.
23. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden
cardiac death in idiopathic dilated cardiomyopathy: the Cardio-
myopathy Trial (CAT). Circulation 2002;105:1453–8.
2004 Katritsis et al. JACC Vol. 60, No. 20, 2012
Nonsustained Ventricular Tachycardia November 13, 2012:1993–2004124. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic
patients with hypertrophic cardiomyopathy and nonsustained ven-
tricular tachycardia. Circulation 1994;90:2743–7.
125. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M,
McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic
cardiomyopathy: an independent marker of sudden death risk in
young patients. J Am Coll Cardiol 2003;42:873–9.
126. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic
evaluation of patients with hypertrophic cardiomyopathy surviving
cardiac arrest. Am J Cardiol 1991;67:280–7.
127. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and
frequency of arrhythmias in hypertrophic cardiomyopathy in relation
to delayed enhancement on cardiovascular magnetic resonance. J Am
Coll Cardiol 2008;51:1369–74.
128. Di Salvo G, Pacileo G, Limongelli G, et al. Non sustained ventricular
tachycardia in hypertrophic cardiomyopathy and new ultrasonic
derived parameters. J Am Soc Echocardiogr 2010;23:581–90.
129. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ.
Spectrum and prognostic significance of arrhythmias on ambulatory
Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2005;45:697–704.
130. O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance
of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll
Cardiol 2010;56:867–74.
131. Maron BJ. Contemporary insights and strategies for risk stratification
and prevention of sudden death in hypertrophic cardiomyopathy.
Circulation 2010;121:445–56.
132. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right
ventricular cardiomyopathy. Lancet 2009;373:1289–300.
133. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable
defibrillator in patients with arrhythmogenic right ventricular cardio-
myopathy/dysplasia and no prior ventricular fibrillation or sustained
ventricular tachycardia. Circulation 2010;122:1144–52.134. Arbelo E, Josephson ME. Ablation of ventricular arrhythmias in
arrhythmogenic right ventricular dysplasia. J Cardiovasc Electro-
physiol 2010;21:473–86.
135. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell
myocarditis—natural history and treatment. Multicenter Giant
Cell Myocarditis Study Group Investigators. N Engl J Med
1997;336:1860 – 6.
136. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhyth-
mia and sudden cardiac death late after repair of tetralogy of Fallot:
a multicentre study. Lancet 2000;356:975–81.
137. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed
ventricular stimulation after tetralogy of Fallot repair: a multicenter
study. Circulation 2004;109:1994–2000.
138. Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in
adults with surgically repaired tetralogy of Fallot: a multi-institutional
study. Circulation 2010;122;868–75.
139. Palladini G, Malamani G, Cò F, et al. Holter monitoring in AL
amyloidosis: prognostic implications. Pacing Clin Electrophysiol
2001;24:1228–33.
140. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular
tachycardia associated with sarcoidosis: assessment of the underlying
cardiac anatomy and the prospective utility of programmed ventric-
ular stimulation, drug therapy and an implantable antitachycardia
device. J Am Coll Cardiol 1991;18:937–43.
141. Sarabanda AV, Marin-Neto JA. Predictors of mortality in patients
with Chagas’ cardiomyopathy and ventricular tachycardia not treated
with implantable cardioverter-defibrillators. Pacing Clin Electro-
physiol 2011;34:54–62.
142. Munoz FD, Syed FF, Noheria A, et al. Characteristics of premature
ventricular complexes as correlates of reduced left ventricular systolic
function: study of the burden, duration, coupling interval, morphology
and site of origin of PVCs. J Cardiovasc Electrophysiol 2011;22:791–8.Key Words: nonsustained y tachycardia y unsustained y ventricular.
